Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

When Connectivity Becomes Critical Care — Webinar

Unregistered doctor convicted after patient is hospitalised following medical procedure

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Smart stormwater system removes harmful pollutants

Researchers create compact supercapacitor designed for reuse

ARRC Gold Coast calls for market certainty on plastics

Making cultivated meat more viable by re-using waste

WA-based Brownes Dairy is back on the market

New Chair of the Western Australian Meat Industry Authority Board

Top 6 impacts of robots, revealed in IFR position paper

What food-grade compressed air actually means